Edgewise Therapeutics, Inc. (EWTX): Total Assets
$552.60M
As of 2025-12-31
$479.69M
As of 2026-06-30
+14.6%
3-year compound annual growth
+33.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $552.60M | +13.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $486.82M | +43.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $340.04M | -7.4% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $367.10M | +28.7% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $285.23M | +117.5% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $131.14M | n/a | 2022-02-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $552.60M | +13.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
| Geron Corp (GERN) | 2025-12-31 | $570.54M | -3.9% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $533.43M | +18.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $513.59M | +213.2% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $594.82M | +10.0% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
Compare EWTX, LAB, GERN, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗